ASH 2024 Lymphomas

CE / CME

ASH 2024 Conference to Clinic: Lymphomas

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: January 14, 2025

Expiration: August 03, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following is true of first-line treatment with acalabrutinib (A) + venetoclax (V) ± obinutuzumab (O) vs chemoimmunotherapy (CIT) in the phase III AMPLIFY trial in patients with CLL, as presented at ASH 2024?

2.

Which of the following therapies given in combination with lenalidomide/rituximab demonstrated improved PFS with a manageable safety profile for patients with R/R FL in the phase III inMIND trial and may represent a potential new standard of care?